Anna Nappi

1.9k total citations
60 papers, 1.1k citations indexed

About

Anna Nappi is a scholar working on Oncology, Radiology, Nuclear Medicine and Imaging and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Anna Nappi has authored 60 papers receiving a total of 1.1k indexed citations (citations by other indexed papers that have themselves been cited), including 26 papers in Oncology, 20 papers in Radiology, Nuclear Medicine and Imaging and 18 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Anna Nappi's work include Colorectal Cancer Treatments and Studies (18 papers), Medical Imaging Techniques and Applications (8 papers) and Hepatocellular Carcinoma Treatment and Prognosis (8 papers). Anna Nappi is often cited by papers focused on Colorectal Cancer Treatments and Studies (18 papers), Medical Imaging Techniques and Applications (8 papers) and Hepatocellular Carcinoma Treatment and Prognosis (8 papers). Anna Nappi collaborates with scholars based in Italy, United Kingdom and United States. Anna Nappi's co-authors include G. Maier, Fortunato Ciardiello, Teresa Troiani, Erika Martinelli, Floriana Morgillo, Vincenzo Sforza, Donata Vitagliano, Anna Capasso, Stefania Napolitano and Annamaria Cividini and has published in prestigious journals such as SHILAP Revista de lepidopterología, Nuclear Physics B and Clinical Cancer Research.

In The Last Decade

Anna Nappi

58 papers receiving 1.1k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Anna Nappi Italy	18	599	270	239	196	173	60	1.1k
Tao Ouyang China	20	568 0.9×	174 0.6×	328 1.4×	436 2.2×	229 1.3×	117	1.3k
Chien-Yuh Yeh Taiwan	21	878 1.5×	364 1.3×	148 0.6×	163 0.8×	111 0.6×	67	1.5k
Qiang Nie China	17	605 1.0×	937 3.5×	327 1.4×	272 1.4×	58 0.3×	66	1.2k
Jintao Hu China	18	281 0.5×	164 0.6×	332 1.4×	252 1.3×	85 0.5×	97	1.1k
Wei Yu China	18	359 0.6×	577 2.1×	359 1.5×	309 1.6×	56 0.3×	96	1.4k
Zhi-Quan Wu China	20	543 0.9×	262 1.0×	535 2.2×	436 2.2×	156 0.9×	61	1.9k
Xinyue Qi China	10	611 1.0×	214 0.8×	225 0.9×	123 0.6×	112 0.6×	30	1.1k
Jiajun Du China	23	934 1.6×	547 2.0×	352 1.5×	333 1.7×	48 0.3×	96	2.0k
Lijuan Niu China	13	364 0.6×	96 0.4×	268 1.1×	109 0.6×	29 0.2×	53	1.1k
Jianfei Fu China	18	342 0.6×	112 0.4×	311 1.3×	307 1.6×	174 1.0×	101	995

Countries citing papers authored by Anna Nappi

Since Specialization

Citations

This map shows the geographic impact of Anna Nappi's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Anna Nappi with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Anna Nappi more than expected).

Fields of papers citing papers by Anna Nappi

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Anna Nappi. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Anna Nappi. The network helps show where Anna Nappi may publish in the future.

Co-authorship network of co-authors of Anna Nappi

This figure shows the co-authorship network connecting the top 25 collaborators of Anna Nappi. A scholar is included among the top collaborators of Anna Nappi based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Anna Nappi. Anna Nappi is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Rosati, Gerardo, Guglielmo Nasti, Alfonso De Stefano, et al.. (2025). A Post Hoc Analysis of Older Patients with Metastatic Colorectal Cancer Receiving Oxaliplatin-Based Chemotherapy Plus Bevacizumab: The Randomized Obelics Study. Drugs & Aging. 42(4). 353–362. 1 indexed citations

Nappi, Anna, et al.. (2025). Primary Mediastinal B-Cell Lymphoma and [18F]FDG PET/CT: What We Learned and What Is New. Hematology Reports. 17(3). 23–23. 1 indexed citations

Dondi, Francesco, Alberto Miceli, Guido Rovera, et al.. (2024). Prostate-Specific Membrane Antigen Radioligand Therapy in Non-Prostate Cancers: Where Do We Stand?. Bioengineering. 11(7). 714–714. 2 indexed citations

Maggialetti, Nicola, Cristina Ferrari, Anna Nappi, et al.. (2024). Is whole body low dose CT still necessary in the era of ¹⁸F-FDG PET/CT for the assessment of bone disease in multiple myeloma patients?. PubMed. 23(3). 264–271. 1 indexed citations

Santo, Giulia, Alberto Miceli, Anna Nappi, et al.. (2023). Clinicians’ perspectives on PET/CT in oncological patients: an Italian National Survey. Clinical and Translational Imaging. 12(1). 99–107. 3 indexed citations

Facchini, Sergio, Francesca Collina, Aurora Daniele, et al.. (2023). 1753P Universal DPYD genotyping in patients with gastrointestinal malignancies: Real-world data from a single institution in Italy. Annals of Oncology. 34. S948–S949. 1 indexed citations

Stefano, Alfonso De, N. Zanaletti, Antonino Cassata, et al.. (2023). Heterogeneous disease and intermittent treatment in metastatic colorectal cancer: A case report. Frontiers in Oncology. 13. 1084681–1084681. 1 indexed citations

Santo, Giulia, Riccardo Laudicella, Flavia Linguanti, et al.. (2022). The Utility of Conventional Amino Acid PET Radiotracers in the Evaluation of Glioma Recurrence also in Comparison with MRI. Diagnostics. 12(4). 844–844. 17 indexed citations

Sardaro, Angela, et al.. (2022). Intracranial Solitary Fibrous Tumor: A “New” Challenge for PET Radiopharmaceuticals. Journal of Clinical Medicine. 11(16). 4746–4746. 4 indexed citations

10.

Frantellizzi, Viviana, Giuseppe Rubini, Angela Spanu, et al.. (2020). Overall survival in mCPRC patients treated with Radium-223 in association with bone health agents: a national multicenter study. International Journal of Radiation Biology. 96(12). 1608–1613. 5 indexed citations

11.

Martinelli, Erika, Giulia Martini, Teresa Troiani, et al.. (2020). 397O Avelumab plus cetuximab in pre-treated RAS wild type metastatic colorectal cancer patients as a rechallenge strategy: The phase II CAVE (cetuximab-avelumab) mCRC study. Annals of Oncology. 31. S409–S410. 16 indexed citations

12.

Alongi, Pierpaolo, et al.. (2020). Brain PET/CT using prostate cancer radiopharmaceutical agents in the evaluation of gliomas. Clinical and Translational Imaging. 8(6). 433–448. 12 indexed citations

13.

Rubini, Giuseppe, Cristina Ferrari, Margherita Fanelli, et al.. (2019). How often suspected pulmonary embolism is diagnosed and its main diagnostic characteristics, in an emergency nuclear medicine service? Four years experience.. CINECA IRIS Institutional Research Information System (University of Bari Aldo Moro). 22(3). 187–193. 3 indexed citations

14.

Cardone, Claudia, Erika Martinelli, Teresa Troiani, et al.. (2019). Exploratory findings from a prematurely closed international, multicentre, academic trial: RAVELLO, a phase III study of regorafenib versus placebo as maintenance therapy after first-line treatment in RAS wild-type metastatic colorectal cancer. ESMO Open. 4(4). e000519–e000519. 4 indexed citations

15.

Ottaiano, Alessandro, Alfonso De Stefano, Monica Capozzi, et al.. (2018). First Biologic Drug in the Treatment of RAS Wild-Type Metastatic Colorectal Cancer: Anti-EGFR or Bevacizumab? Results From a Meta-Analysis. Frontiers in Pharmacology. 9. 441–441. 9 indexed citations

16.

Nappi, Anna, Massimiliano Berretta, Carmela Romano, et al.. (2017). Metastatic Colorectal Cancer: Role of Target Therapies and Future Perspectives. Current Cancer Drug Targets. 18(5). 421–429. 53 indexed citations

17.

Trotta, Anna Maria, Alessandro Ottaiano, Carmela Romano, et al.. (2016). Prospective Evaluation of Cetuximab-Mediated Antibody-Dependent Cell Cytotoxicity in Metastatic Colorectal Cancer Patients Predicts Treatment Efficacy. Cancer Immunology Research. 4(4). 366–374. 62 indexed citations

18.

D’Alterio, Crescenzo, Guglielmo Nasti, Alessandro Ottaiano, et al.. (2016). CXCR4–CXCL12–CXCR7, TLR2–TLR4, and PD-1/PD-L1 in colorectal cancer liver metastases from neoadjuvant-treated patients. OncoImmunology. 5(12). e1254313–e1254313. 39 indexed citations

19.

Troiani, Teresa, Stefania Napolitano, Donata Vitagliano, et al.. (2014). Primary and Acquired Resistance of Colorectal Cancer Cells to Anti-EGFR Antibodies Converge on MEK/ERK Pathway Activation and Can Be Overcome by Combined MEK/EGFR Inhibition. Clinical Cancer Research. 20(14). 3775–3786. 83 indexed citations

20.

Troiani, Teresa, Erika Martinelli, Stefania Napolitano, et al.. (2013). Increased TGF-α as a Mechanism of Acquired Resistance to the Anti-EGFR Inhibitor Cetuximab through EGFR–MET Interaction and Activation of MET Signaling in Colon Cancer Cells. Clinical Cancer Research. 19(24). 6751–6765. 125 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact